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Free Paper Presentations CFP10 (25 mg/mL); A2,A3 negative controls consisted of cells cultured with medium alone; B2,B3 positive controls consisted of cells cultured with Con A (25 mg/mL).
Results: The CFP-10 recombinant protein were obtained and purified, In-house ELISPOT IFN-g assay using recombinant CFP-10 antigen show significant high frequencies TB specific T-cell responses in patients of active TB with or without HIV infection. there was 100% consistency to the clinical manifestation, in the HIV(+) group without clinical TB disease, the rate of positive tests results was 24.7%. Our results proved that it is indeed true that some of HIV positive patient have high frequencies of TB specific T-cell responses, it could be used in diagnosis of TB diseases, and it maybe provide a clue to find latent TB infection in Chinese HIV(+) population. The pathogenesis of HPS is presumed to result from an enhanced proinflammatory cytokine secretion and systemic macrophage activation. Previously, we demonstrated that EBV LMP-1 can activate T-cells and upregulate tumor necrosis factor-alpha and interferon-gamma, mediated through the NFkB/ATF5/SAP/ERK signaling, to activate macrophages. Since peroxisome proliferators activated receptor (PPAR) agonists, regulators of cholesterol metabolism, have been shown to exhibit profound effects on the inhibition of proinflammatory cytokines and macrophage activation through NFkB and AP-1 signaling, we adopted a PPAR-g agonist, rosiglitazone, for the potential therapy of HPS using a rabbit model of Herpesvirus papio (HVP, an EBV homologue)-associated HPS. Materials and Results: In vitro, rosiglitazone was shown to inhibit macrophage activation and secretion of tumor necrosis factor-alpha (TNF-a) through inhibition of NFkB signaling in THP1 cell line. Different doses of rosiglitazone were then fed to rabbits after intravenous injection of 5×107 copies of HVP virus at different time courses (7 days and 20 days, respectively) of infection. As compared to the control group which succumbed consistently at around one month, the 4 mg rosiglitazone-treated group showed significant improvement of survival when fed at early stage (7 days) of infection (p < 0.01), while a higher dosage (8 mg) is needed to achieve therapeutic effect at advanced stage (20 days) of infection (p < 0.05). The viral load, TNFa cytokine levels, and laboratory parameters also showed significant improvement in the rosiglitazone-treated group.
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Conclusion: PPAR agonist, in addition to its therapeutic effect for metabolic syndrome, appears to represent a potential regimen of new concept for the control of HPS associated with severe virus infections. Results: PCR analysis did not reveal a significant diference in the prevalence of latent/persistent HHV-7 infection
